Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00752141 · ClinicalTrials.gov registry record · Phase 1
Cognitive Effects of Oral Oxybutynin and Oxybutynin Chloride Topical Gel in Older Volunteers
A Phase 1 study, sponsored by Watson Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 153
- Enrollment target
NCT00752141 is a Phase 1 study that has completed, run by Watson Pharmaceuticals. The registered enrollment target is 153 participants.
The verdict
NCT00752141, a Phase 1 study, has completed, sponsored by Watson Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 153 participants
- Enrollment target
Study Summary
The purpose of this study is to explore the possible cognitive effects of oxybutynin tablets and oxybutynin gel.
Interventions
- OTHER placebo
- DRUG oxybutynin chloride immediate-release
- DRUG oxybutynin chloride topical gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2008-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00752141
The ClinicalTrials.gov registry entry for NCT00752141 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Watson Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00752141 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00752141 about?
NCT00752141 is a clinical study titled "Cognitive Effects of Oral Oxybutynin and Oxybutynin Chloride Topical Gel in Older Volunteers". The purpose of this study is to explore the possible cognitive effects of oxybutynin tablets and oxybutynin gel.
What is the current status of trial NCT00752141?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 153 participants. The study started on 2008-09.
What interventions are being tested in trial NCT00752141?
The interventions under investigation include: placebo (OTHER), oxybutynin chloride immediate-release (DRUG), oxybutynin chloride topical gel (DRUG).
Who is sponsoring clinical trial NCT00752141?
This trial is sponsored by Watson Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.